AtaiBeckley Inc. (ATAI)Healthcare | Biotechnology | New York, United States | NasdaqGM
7.29 USD
-0.06
(-0.816%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.29 |
Hot Take ↕ | Aug. 22, 2026, 1:26 a.m. EDT
The immediate catalyst here is the reported acquisition by Eli Lilly for $2.8 billion, which has transformed AtaiBeckley from a distressed biotech into a takeover target. While the company's standalone fundamentals are catastrophic—showing a multi-year price collapse, negative earnings, and a P/S ratio of 612x—the market is pricing in the acquisition value rather than the business quality. The options market confirms this with a massive skew toward calls, suggesting traders expect the stock to rally significantly as the deal progresses. However, the long-term investment thesis remains broken; the company has suffered a 71% decline over the last four years and continues to burn cash with no path to profitability. The current price is not a reflection of sustainable value creation but rather a premium paid for the certainty of an exit. Investors should view this as a short-to-intermediate momentum play on the deal completion, not a long-term equity investment in the company itself. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.430793 |
| AutoETS | 0.447545 |
| AutoTheta | 0.454536 |
| MSTL | 0.463254 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 5.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.018 |
| Excess Kurtosis | -0.99 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.429 |
| Revenue per Share | 0.014 |
| Market Cap | 2,703,603,456 |
| Forward P/E | -14.88 |
| Beta | 1.55 |
| Previous Name | Atai Life Sciences N.V. |
| Website | https://www.ataibeckley.com |
As of Aug. 22, 2026, 1:26 a.m. EDT: Speculators are heavily positioned for upside, evidenced by massive open interest in out-of-the-money calls (strikes 8.0 and 12.0) compared to negligible put volume. The call chain shows significant 'top OI' at strikes well above the current price, while the put side is almost entirely comprised of ATM anchors with minimal speculative downside protection. This asymmetry indicates a market consensus betting on a significant price appreciation driven by the acquisition news.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.58823526 |
| Address1 | 250 West 34th Street |
| All Time High | 22.91 |
| All Time Low | 1.025 |
| Ask | 7.2 |
| Ask Size | 2 |
| Average Analyst Rating | 2.9 - Hold |
| Average Daily Volume10 Day | 7,206,710 |
| Average Daily Volume3 Month | 12,030,888 |
| Average Volume | 12,030,888 |
| Average Volume10Days | 7,206,710 |
| Beta | 1.553 |
| Bid | 7.17 |
| Bid Size | 59 |
| Book Value | 0.478 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.29 |
| Current Ratio | 8.578 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.37 |
| Day Low | 7.29 |
| Debt To Equity | 2.429 |
| Display Name | AtaiBeckley |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -140,791,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -17.63 |
| Enterprise To Revenue | 555.043 |
| Enterprise Value | 2,482,151,424 |
| Eps Current Year | -0.43181 |
| Eps Forward | -0.48997 |
| Eps Trailing Twelve Months | -2.77 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.4127 |
| Fifty Day Average Change | 0.8772998 |
| Fifty Day Average Change Percent | 0.1368066 |
| Fifty Two Week Change Percent | 58.823524 |
| Fifty Two Week High | 7.45 |
| Fifty Two Week High Change | -0.15999985 |
| Fifty Two Week High Change Percent | -0.02147649 |
| Fifty Two Week Low | 3.265 |
| Fifty Two Week Low Change | 4.0249996 |
| Fifty Two Week Low Change Percent | 1.2327716 |
| Fifty Two Week Range | 3.265 - 7.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,023,000,000 |
| Float Shares | 308,411,059 |
| Forward Eps | -0.48997 |
| Forward P E | -14.878462 |
| Free Cashflow | -74,669,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 99 |
| Fullday Change | -0.0599999 |
| Fullday Change Percent | -0.816326 |
| Fullday Price | 7.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -70,624,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02183 |
| Held Percent Institutions | 0.53107 |
| Implied Shares Outstanding | 370,864,669 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-18 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. |
| Long Name | AtaiBeckley Inc. |
| Market | us_market |
| Market Cap | 2,703,603,456 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_710359021 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -668,193,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,725,855,317 |
| Number Of Analyst Opinions | 7 |
| Open | 7.345 |
| Operating Cashflow | -127,103,000 |
| Operating Margins | -25.90434 |
| Payout Ratio | 0.0 |
| Phone | 332 282 0507 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.29 |
| Post Market Time | 1,787,959,805 |
| Prev Name | Atai Life Sciences N.V. |
| Previous Close | 7.35 |
| Price Eps Current Year | -16.882425 |
| Price Hint | 2 |
| Price To Book | 15.251046 |
| Price To Sales Trailing12 Months | 604.5625 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.285 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.85714 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -0.816326 |
| Regular Market Day High | 7.37 |
| Regular Market Day Low | 7.29 |
| Regular Market Day Range | 7.29 - 7.37 |
| Regular Market Open | 7.345 |
| Regular Market Previous Close | 7.35 |
| Regular Market Price | 7.29 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 2,530,914 |
| Return On Assets | -0.39026 |
| Return On Equity | -4.17207 |
| Revenue Growth | 1.37 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 370,864,669 |
| Shares Percent Shares Out | 0.0454 |
| Shares Short | 16,855,502 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 37,787,570 |
| Short Name | AtaiBeckley Inc. |
| Short Percent Of Float | 0.053600002 |
| Short Ratio | 0.95 |
| Source Interval | 15 |
| State | NY |
| Symbol | ATAI |
| Target High Price | 9.25 |
| Target Low Price | 7.45 |
| Target Mean Price | 8.1 |
| Target Median Price | 8.0 |
| Total Cash | 225,808,000 |
| Total Cash Per Share | 0.609 |
| Total Debt | 4,285,000 |
| Total Revenue | 4,472,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.586625 |
| Two Hundred Day Average Change | 2.7033749 |
| Two Hundred Day Average Change Percent | 0.5894039 |
| Type Disp | Equity |
| Volume | 2,530,914 |
| Website | https://www.ataibeckley.com |
| Zip | 10,119 |